You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

Investigational Drug Information for SHR4640

✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug SHR4640?

SHR4640 is an investigational drug.

There have been 18 clinical trials for SHR4640. The most recent clinical trial was a Phase 2 trial, which was initiated on July 30th 2019.

The most common disease conditions in clinical trials are Hyperuricemia, Gout, and Arthritis, Gouty. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd., and [disabled in preview].

There is one US patent protecting this investigational drug and thirty-five international patents.

Recent Clinical Trials for SHR4640
PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT IntervalJiangsu HengRui Medicine Co., Ltd.Phase 1
Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy SubjectsJiangsu HengRui Medicine Co., Ltd.Phase 1
Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and HyperuricemiaJiangsu HengRui Medicine Co., Ltd.Phase 2

See all SHR4640 clinical trials

Clinical Trial Summary for SHR4640

Top disease conditions for SHR4640
Top clinical trial sponsors for SHR4640

See all SHR4640 clinical trials

International Patents for SHR4640

Drugname Country Document Number Estimated Expiration Related US Patent
SHR4640 Australia AU2016368240 2035-12-07 ⤷  Sign Up
SHR4640 Brazil BR112018011390 2035-12-07 ⤷  Sign Up
SHR4640 Canada CA3007783 2035-12-07 ⤷  Sign Up
SHR4640 China CN106831569 2035-12-07 ⤷  Sign Up
SHR4640 China CN106831570 2035-12-07 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.